Life Extension Forums dotNetBB Forums : Join the Revolution dotNetBB Forums : Join the Revolution dotNetBB Forums : Join the Revolution dotNetBB Forums : Join the Revolution
Announcement Attention: Important Forum Announcement
 
The Life Extension Foundation Forums > LEF Public Forums > Disorders/Diseases > Beta 2 Agonists and Weight Loss  Forum Quick Jump
 
You cannot post new topics in this forum. You cannot reply to topics in this forum. Printable Version
[ << Previous Thread | Next Thread >> | Show Newest Post First ]

robert
Registered Member

Email Address Not AvailablePersonal Homepage Not AvailableAIM Not AvailableICQ Not AvailableY! Not AvailableMSN Not Available
Date Joined Jul 2002
Total Posts : 58
 
   Posted 5/22/1999 9:00 PM (GMT -4)    Quote This PostAlert An Admin About This Post.
Could you explain in laymans terms what beta-2 agonists are? Are they a safe and effective way to lose fat? Do you have any opinion on the banned drug Clenbuterol? Should it be taken with meals or on an empty stomach? .

Thanks in advance. . .

::I know little of this area, but here are a couple of things that I found.

For weight loss you want beta-3 adrenoreceptor agonists, beta-2 agonists are used to conrol asthsma. Here is a review abstract:

Diabetes Metab 1999 Mar;25(1):11-21 .
Development of beta3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
Weyer C, Gautier JF, Danforth E Jr
National Institutes of Health, Phoenix, AZ. cweyer@phx.niddk.nih.gov

Beta3-adrenoceptor (beta 3-AR) agonists were found to have remarkable anti-obesity and anti-diabetic effects in rodents shortly after their discovery in the early 1980s. Despite these promising qualities, several pharmaceutical problems and theoretical concerns have slowed the development of these products as therapeutic agents in humans during the last 15 years. To date, the pharmaceutical industry has not been successful in developing a beta 3-AR agonist for use in the treatment of human obesity and type 2 diabetes. Pharmaceutical problems in this area concern important differences between rodent and human beta 3-AR and the difficulty in finding a compound with sufficient bioavailability that is a highly selective and full agonist at the human receptor. Some of these problems seem to have been solved with the cloning of the human beta 3-AR, which has made it possible to develop novel compounds directly and specifically against the human receptor. However, several theoretical concerns still remain. These include the major question as to whether the number of biologically active beta 3-ARs in adult humans is sufficient to produce relevant metabolic effects and, if so, whether their long-term stimulation is safe and free of unwarranted side effects. In addition, the mechanisms of action of beta 3-AR agonists remain poorly understood. Recent studies using CL 316,243, a highly selective beta 3-adrenergic compound, have provided new insights into the potential mechanisms of action of these drugs in rodents as well as the first evidence that treatment with a highly selective beta 3-AR agonist exerts relevant metabolic effects in humans. It appears that chronic beta 3-adrenergic stimulation in white adipose tissue increases the expression of newly discovered mitochondrial uncoupling proteins (UCP 2 and 3) and a reawakening of dormant brown adipocytes. In addition, beta 3-ARs may be present in skeletal muscle where ectopic expression of UCP-1 has been reported. If these findings are confirmed, tissues other than brown fat may play an important role in mediating beta 3-adrenergic effects on thermogenesis and substrate oxidation. In humans, treatment with CL 316,243 for 8 weeks, in spite of limited bioavailability, induced marked plasma concentration-dependent increases in insulin sensitivity, lipolysis, and fat oxidation in lean volunteers, without causing beta 1-, or beta 2-mediated side effects. These results clearly indicate that favourable metabolic effects can be achieved by selective beta 3-AR stimulation in humans. The compounds of the next generation currently emerging from preclinical development are full agonists at the human beta 3-AR. These agents have demonstrated promising results in non-human primates. It will be interesting to see whether their efficacy in clinical trials is superior to that achieved with previous (rodent) beta 3-AR agonists and, if so, whether their effects will eventually translate into weight loss and improved metabolic control that could facilitate their use as effective drugs for the treatment of obesity and Type 2 diabetes in humans.

Clenbuterol is classified as a broncodillator and tocolytic (supresses premature labor. You might get it by prescription from a cooperative physician. It is also used by veterinarians. I found some reference to its reproductive toxicology and that may be why it was banned. ::
Back to Top
 
You cannot post new topics in this forum. You cannot reply to topics in this forum. Printable Version
 
Forum Information
Currently it is Friday, October 24, 2014 8:05 PM (GMT -4)
There are a total of 38,084 posts in 7,744 threads.
In the last 3 days there were 0 new threads and 0 reply posts. View Active Threads
Who's Online
This forum has 9706 registered members. Please welcome our newest member, LivingLongHopefully.
1 Guest(s), 0 Registered Member(s) are currently online.  Details